NCT04279470View on ClinicalTrials.gov

Chimeric Antigen Receptor T-cell and Cellular Therapies for the Treatment of cAncer or BLood Diseases: Evaluation of Reporting of Adverse Events

CompletedOBSERVATIONAL

Enrollment

100,000

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

January 1, 2023

Study Completion Date

April 8, 2023

Conditions

Adverse Drug ReactionsCancer

Interventions

DRUG

CAR T-cell and Cellular Therapies

Chimeric Antigen Receptor T-cell and Cellular Therapies for the treatment of a cancer either solid or hematologic malignancy

Trial Locations (1)

75013

Hôpital Pitié-Salpêtrière, Paris

All Listed Sponsors

lead

Groupe Hospitalier Pitie-Salpetriere

OTHER

NCT04279470 - Chimeric Antigen Receptor T-cell and Cellular Therapies for the Treatment of cAncer or BLood Diseases: Evaluation of Reporting of Adverse Events | Biotech Hunter | Biotech Hunter